[{"address1": "2001 Market Street", "address2": "Suite 3915 Unit #15", "city": "Philadelphia", "state": "PA", "zip": "19103", "country": "United States", "phone": "(267) 225-7416", "website": "https://www.contexttherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Mr. Martin A. Lehr", "age": 39, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1984, "fiscalYear": 2022, "totalPay": 725250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Minai-Azary", "age": 45, "title": "CFO & Treasurer", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": 533655, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex C. Levit Esq.", "age": 44, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": 512100, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Beck M.B.A.", "title": "Senior Vice President of Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.31, "open": 1.3, "dayLow": 1.3, "dayHigh": 1.3908, "regularMarketPreviousClose": 1.31, "regularMarketOpen": 1.3, "regularMarketDayLow": 1.3, "regularMarketDayHigh": 1.3908, "beta": 2.173, "forwardPE": -1.915493, "volume": 13917, "regularMarketVolume": 13917, "averageVolume": 56782, "averageVolume10days": 53430, "averageDailyVolume10Day": 53430, "marketCap": 21713896, "fiftyTwoWeekLow": 0.47, "fiftyTwoWeekHigh": 1.69, "fiftyDayAverage": 1.22306, "twoHundredDayAverage": 1.124325, "currency": "USD", "enterpriseValue": 7264005, "floatShares": 13889029, "sharesOutstanding": 15966100, "sharesShort": 11223, "sharesShortPriorMonth": 10782, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0007, "heldPercentInsiders": 0.06861, "heldPercentInstitutions": 0.3006, "shortRatio": 0.16, "shortPercentOfFloat": 0.0008, "impliedSharesOutstanding": 15966100, "bookValue": 0.744, "priceToBook": 1.8279569, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -23964212, "trailingEps": -1.5, "forwardEps": -0.71, "enterpriseToEbitda": -0.29, "52WeekChange": 1.357019, "SandP52WeekChange": 0.23061275, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CNTX", "underlyingSymbol": "CNTX", "shortName": "Context Therapeutics Inc.", "longName": "Context Therapeutics Inc.", "firstTradeDateEpochUtc": 1634736600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9370db4d-3fc8-33de-8dd0-aba14eeca611", "messageBoardId": "finmb_408000800", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.36, "targetHighPrice": 4.0, "targetLowPrice": 2.1, "targetMeanPrice": 3.37, "targetMedianPrice": 4.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 14449827, "totalCashPerShare": 0.905, "ebitda": -25060572, "quickRatio": 3.447, "currentRatio": 3.828, "returnOnAssets": -0.58008, "returnOnEquity": -1.02786, "freeCashflow": -12783431, "operatingCashflow": -21047618, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-23"}]